Chronic Gingivostomatitis Treatment Market, by Diagnosis, by Treatment, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

PUBLISHED: May 31, 2022

PAGES: 180 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Gingivostomatitis is a contagious mouth infection, which causes painful sores, blisters, and swelling in the tongue and uvula. It usually spreads through the saliva of an infected individual or by direct contact with a lesion or sore. Gingivostomatitis is also called as herpetic, which is caused by herpes simplex virus and is the most common cause of gingivostomatitis. Gingivostomatitis is the most common among young children, usually under 6 years old, but it may also occur in adults. Geriatric people may experience severe symptoms than adults and children.

Market Dynamics

Rising incidence of gingivostomatitis caused by herpes simplex virus (HSV) is expected to drive the chronic gingivostomatitis treatment market growth. For instance, according to the International Journal of Dentistry, an article published in October 2016, reports that over 90% of gingivostomatitis cases are caused by herpes simplex virus (HSV) type 1 and the remainder are caused by herpes simplex virus (HSV) type 2.

However, lack of identification or diagnosis of chronic gingivostomatitis are expected to hinder the market growth. For instance, according to the Journal of Dental Health Oral Disorders & Therapy, an article published in 2017, states that chronic gingivostomatitis may be asymptomatic in some instances, may be unnoticed in some instances, and sometimes get misdiagnosed with other chronic mouth ulcers.

Key features of the study:

This report provides in-depth analysis of the global chronic gingivostomatitis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic gingivostomatitis treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc. among others
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global chronic gingivostomatitis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic gingivostomatitis treatment market

Detailed Segmentation:

Global Chronic Gingivostomatitis Treatment Market, By Diagnosis:
- Physical Examination
- Microbial Culture
- Biopsy
- Others
Global Chronic Gingivostomatitis Treatment Market, By Treatment:
- Non-steroidal Anti-inflammatory Drugs
- Antiviral
- Antibacterial
- Others
Global Chronic Gingivostomatitis Treatment Market, By End User:
- Hospitals & Clinics
- Academic & Research
- Others
Global Chronic Gingivostomatitis Treatment Market, By Region:
- North America
  - By Diagnosis:
  - Physical Examination
  - Microbial Culture
  - Biopsy
  - Others
  - By Treatment:
  - Non-steroidal Anti-inflammatory Drugs
  - Antiviral
  - Antibacterial
  - Others
  - By End User:
  - Hospitals & Clinics
  - Academic & Research
  - Others
  - By Country:
  - U.S.
  - Canada
- Latin America
  - By Diagnosis:
  - Physical Examination
  - Microbial Culture
  - Biopsy
  - Others
  - By Treatment:
  - Non-steroidal Anti-inflammatory Drugs
  - Antiviral
  - Antibacterial
  - Others
  - By End User:
  - Hospitals & Clinics
  - Academic & Research
  - Others
  - By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Drug Type:
  - By Diagnosis:
  - Physical Examination
  - Microbial Culture
  - Biopsy
  - Others
  - By Treatment:
  - Non-steroidal Anti-inflammatory Drugs
  - Antiviral
  - Antibacterial
  - Others
  - By End User:
  - Hospitals & Clinics
  - Academic & Research
  - Others
  - By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Diagnosis:
  - Physical Examination
  - Microbial Culture
  - Biopsy
  - Others
  - By Treatment:
  - Non-steroidal Anti-inflammatory Drugs
  - Antiviral
  - Antibacterial
  - Others
  - By End User:
  - Hospitals & Clinics
  - Academic & Research
  - Others
  - By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Diagnosis:
  - Physical Examination
  - Microbial Culture
  - Biopsy
  - Others
  - By Treatment:
  - Non-steroidal Anti-inflammatory Drugs
  - Antiviral
  - Antibacterial
  - Others
  - By End User:
  - Hospitals & Clinics
  - Academic & Research
  - Others
  - By Country:
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Diagnosis:
  - Physical Examination
  - Microbial Culture
  - Biopsy
  - Others
  - By Treatment:
  - Non-steroidal Anti-inflammatory Drugs
  - Antiviral
  - Antibacterial
  - Others
  - By End User:
  - Hospitals & Clinics
  - Academic & Research
  - Others
  - By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- Pfizer Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Taj Pharmaceutical limited.
- Ciron pharma
- Johnson & Johnson
- GlaxoSmithKline PLC
- Merck & CO., Inc.
- Novartis AG
- F. Hoffman La Roche AG
- Eli Lily and Company
- AstraZeneca Plc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI4308

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Diagnosis
- Market Snippet, By Treatment
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
Reimbursement Scenario
Epidemiology
Pest Analysis
Regulatory Scenario
New Product Launches
Collaborations and Agreements
Market Trends

4. Global Chronic Gingivostomatitis Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Market Scenario
Impact of COVID-19 Market on the Chronic Gingivostomatitis Treatment Products

5. Global Chronic Gingivostomatitis Treatment Market, By Diagnosis, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Physical Examination
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Microbial Culture
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Chronic Gingivostomatitis Treatment Market, By Treatment, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Non-steroidal Anti-inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Antiviral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Antibacterial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Chronic Gingivostomatitis Treatment Market, By End User, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospitals & Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Academic & Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Global Chronic Gingivostomatitis Treatment Market, By Region, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
North America
- Market Size and Forecast, By Diagnosis, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Diagnosis, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Diagnosis, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Diagnosis, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Diagnosis, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Diagnosis, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa

9. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Taj Pharmaceutical limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ciron pharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline PLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & CO., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- F. Hoffman La Roche AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eli Lily and Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca Plc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views